tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Myelitis D009187 1 associated lipids
IgG Deficiency D017099 1 associated lipids
Deltaretrovirus Infections D006800 1 associated lipids
Hepatopulmonary Syndrome D020065 1 associated lipids
Herpes Labialis D006560 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Nocturnal Myoclonus Syndrome D020189 1 associated lipids
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Polymyositis D017285 1 associated lipids
Scorpion Stings D065008 1 associated lipids
Rotavirus Infections D012400 1 associated lipids
Netherton Syndrome D056770 1 associated lipids
Lymphocytic Choriomeningitis D008216 1 associated lipids
Erythroplasia D004919 1 associated lipids
Hepatic Veno-Occlusive Disease D006504 1 associated lipids
West Nile Fever D014901 1 associated lipids
Hypoalbuminemia D034141 1 associated lipids
Arm Injuries D001134 1 associated lipids
Intussusception D007443 1 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Autoimmune Diseases of the Nervous System D020274 1 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Central Serous Chorioretinopathy D056833 1 associated lipids
Feline Acquired Immunodeficiency Syndrome D016181 1 associated lipids
Budd-Chiari Syndrome D006502 1 associated lipids
AIDS-Associated Nephropathy D016263 1 associated lipids
Oral Ulcer D019226 1 associated lipids
Epidermolysis Bullosa Dystrophica D016108 1 associated lipids
Primary Graft Dysfunction D055031 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Epididymitis D004823 1 associated lipids
Pruritus Vulvae D011539 1 associated lipids
Cervical Intraepithelial Neoplasia D018290 1 associated lipids
Migraine with Aura D020325 1 associated lipids
Porokeratosis D017499 1 associated lipids
Lentigo D007911 1 associated lipids
Mutism D009155 1 associated lipids
Amyloid Neuropathies D017772 1 associated lipids
Meningitis, Fungal D016921 1 associated lipids
Malocclusion, Angle Class II D008312 1 associated lipids
Flaviviridae Infections D018178 1 associated lipids
Idiopathic Interstitial Pneumonias D054988 1 associated lipids
Dysuria D053159 1 associated lipids
Denys-Drash Syndrome D030321 1 associated lipids
Akinetic Mutism D000405 1 associated lipids
Sleep Apnea, Central D020182 1 associated lipids
Orchitis D009920 1 associated lipids
Phyllodes Tumor D003557 1 associated lipids
Priapism D011317 1 associated lipids
Vulvar Lichen Sclerosus D007724 1 associated lipids
Cardiomyopathy, Restrictive D002313 1 associated lipids
Paraparesis, Tropical Spastic D015493 1 associated lipids
Neurodermatitis D009450 1 associated lipids
Posterior Leukoencephalopathy Syndrome D054038 1 associated lipids
Ecthyma, Contagious D004474 1 associated lipids
Panniculitis, Lupus Erythematosus D015435 1 associated lipids
Retrognathia D063173 1 associated lipids
Mediastinal Diseases D008477 1 associated lipids
Hypophosphatemia D017674 1 associated lipids
Leukemia, Myeloid, Chronic-Phase D015466 1 associated lipids
Myelinolysis, Central Pontine D017590 1 associated lipids
Protoporphyria, Erythropoietic D046351 1 associated lipids
Smooth Muscle Tumor D018235 1 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Ichthyosiform Erythroderma, Congenital D016113 1 associated lipids
Poxviridae Infections D011213 1 associated lipids
Kaposi Varicelliform Eruption D007617 1 associated lipids
Lacerations D022125 1 associated lipids
Megacolon, Toxic D008532 1 associated lipids
Tinea Capitis D014006 1 associated lipids
Digestive System Fistula D016154 1 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Leukoplakia, Oral D007972 1 associated lipids
Peroneal Neuropathies D020427 1 associated lipids
Polyomavirus Infections D027601 1 associated lipids
Lymphohistiocytosis, Hemophagocytic D051359 1 associated lipids
Rheumatoid Nodule D012218 1 associated lipids
Hernia, Ventral D006555 1 associated lipids
Hepatitis, Autoimmune D019693 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
Echinostomiasis D004451 1 associated lipids
Multiple Endocrine Neoplasia Type 2a D018813 1 associated lipids
Apraxias D001072 1 associated lipids
Hypertensive Encephalopathy D020343 1 associated lipids
Hearing Loss, Bilateral D006312 1 associated lipids
Nocturia D053158 1 associated lipids
Citrullinemia D020159 1 associated lipids
Pulmonary Veno-Occlusive Disease D011668 1 associated lipids
Sweet Syndrome D016463 1 associated lipids
Optic Neuritis D009902 1 associated lipids
Granuloma Annulare D016460 1 associated lipids
Paraneoplastic Syndromes, Nervous System D020361 1 associated lipids
Intestinal Fistula D007412 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Nephritis, Hereditary D009394 1 associated lipids
Mastocytosis, Cutaneous D034701 1 associated lipids
Pancreatitis, Graft D055589 1 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Fryer JP et al. Bacterial translocation in a large-animal model of small-bowel transplantation. Portal vs systemic venous drainage and the effect of tacrolimus immunosuppression. 1996 Arch Surg pmid:8546583
Bechstein WO et al. Tacrolimus (FK 506) therapy is associated with a significant reduction in immunosuppressive treatment failures following primary liver transplantation. 1996 Transplant. Proc. pmid:8623211
Sher LS et al. Tacrolimus (FK 506) for rescue of chronic rejection following orthotopic liver transplantation. 1996 Transplant. Proc. pmid:8623212
Millis JM et al. Treatment of steroid-resistant rejection with tacrolimus prior to OKT3 in liver transplant recipients. 1996 Transplant. Proc. pmid:8623213
Washburn WK et al. Tacrolimus rescue therapy for renal allograft rejection refractory to cyclosporine-based immunosuppression. 1996 Transplant. Proc. pmid:8623214
Delaney CP et al. Allogeneic hematolymphoid microchimerism and prevention of autoimmune disease in the rat. A relationship between allo- and autoimmunity. 1996 J. Clin. Invest. pmid:8550837
Regazzi MB et al. Interaction between FK 506 and diltiazem in an animal model. 1996 Transplant. Proc. pmid:8623215
Hashikura Y et al. Immunosuppressant switching between cyclosporine and tacrolimus after liver transplantation. 1996 Transplant. Proc. pmid:8623218
Tomikawa S et al. Immunosuppressive effects of bactobolamine in vitro and in vivo. 1996 Transplant. Proc. pmid:8623223
Nakajima H and Oka T The inhibition of T-cell-receptor-induced Fas ligand upregulation by cyclosporine and FK 506. 1996 Transplant. Proc. pmid:8623224
Elmer DS et al. Use of FK506 immunosuppressive therapy in pancreas transplantation. 1996 J Transpl Coord pmid:9188369
Ciancio G et al. Human donor bone marrow cells can enhance hyporeactivity in renal transplantation using maintenance FK 506 and OKT3 induction therapy. 1996 Transplant. Proc. pmid:8623473
D'Silva M et al. Immunosuppressive effect of brequinar on rat cardiac allograft survival in combination with leflunomide or FK 506. 1996 Transplant. Proc. pmid:8623476
Klintmalm GB Clinical use of FK 506 in liver transplantation. 1996 Transplant. Proc. pmid:8623484
Butt TR et al. Molecular basis of immunosuppressive drug action: regulation of steroid receptor-mediated transcription by FK 506. 1996 Transplant. Proc. pmid:8623486
Troppmann C et al. Perioperative immunosuppression as a critical determinant of early outcome after discordant xenoislet transplantation: a comparative study. 1996 Transplant. Proc. pmid:8623487
Chudek J et al. [The role of endothelin in the physiology and pathophysiology of the circulatory system and kidneys]. 1996 Pol. Arch. Med. Wewn. pmid:9139279
Kawashima M et al. Tacrolimus concentrations in blood during topical treatment of atopic dermatitis. 1996 Lancet pmid:8898050
Drake M et al. The immunosuppressant FK506 ameliorates ischaemic damage in the rat brain. 1996 Acta Physiol. Scand. pmid:8899062
Beauparlant P and Hiscott J Biological and biochemical inhibitors of the NF-kappa B/Rel proteins and cytokine synthesis. 1996 Cytokine Growth Factor Rev. pmid:8899295
Kaplan B et al. Frequency of hyperkalemia in recipients of simultaneous pancreas and kidney transplants with bladder drainage. 1996 Transplantation pmid:8900321
Min DI et al. Circadian variation of tacrolimus disposition in liver allograft recipients. 1996 Transplantation pmid:8900327
Brazelton TR and Morris RE Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. 1996 Curr. Opin. Immunol. pmid:8902398
Corrigan CJ et al. Glucocorticoid resistant asthma: T-lymphocyte steroid metabolism and sensitivity to glucocorticoids and immunosuppressive agents. 1996 Eur. Respir. J. pmid:8902470
Dmitrewski J et al. Recurrence of primary biliary cirrhosis in the liver allograft: the effect of immunosuppression. 1996 J. Hepatol. pmid:8778189
Sakane T and Miura K [Research for basic and clinical aspects of Behcet's disease--recent advance and future--]. 1996 Nippon Rinsho pmid:8904250
Schwarz A [Drug-induced kidney damage]. 1996 Z Arztl Fortbild (Jena) pmid:8779233
Newell KA et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. 1996 Transplantation pmid:8779685
Lufft V et al. Incidence of Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression. 1996 Transplantation pmid:8779695
Craescu CT et al. Three-dimensional structure of the immunophilin-like domain of FKBP59 in solution. 1996 Biochemistry pmid:8780506
Singh N and Yu VL Prophylaxis for cytomegalovirus disease after liver transplant. 1996 Clin. Infect. Dis. pmid:8783744
Sperr WR et al. Effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells. 1996 J. Allergy Clin. Immunol. pmid:8757216
Venkataraman L et al. Differential regulation of c-Rel translocation in activated B and T cells. 1996 J. Immunol. pmid:8757620
Asfar S et al. Small bowel transplantation. 1996 Transplant. Proc. pmid:8908039
Reyes J et al. Intestinal transplantation in children: five-year experience. 1996 Transplant. Proc. pmid:8908042
Rao AS et al. Augmentation of natural chimerism with donor bone marrow in orthotopic liver recipients. 1996 Transplant. Proc. pmid:8908140
Alper G and Small SL Cerebrospinal fluid after organ transplantation. 1996 Transplant. Proc. pmid:8908142
Namieno T and Uchino J Comparative study of the effects of cyclosporine and FK 506 on rat hepatocytes cocultured with nonparenchymal liver cells. 1996 Transplant. Proc. pmid:8908147
Williams R et al. Two-year data from the European multicentre tacrolimus (FK506) liver study. 1996 Transpl. Int. pmid:8959812
Jonas S et al. Indications for tacrolimus anti-rejection therapy in liver allograft recipients. 1996 Transpl. Int. pmid:8959817
Jonas S et al. Conversion to tacrolimus after liver transplantation. 1996 Transpl. Int. pmid:8748407
Cooley HM et al. Resolution of pyoderma gangrenosum using tacolimus (FK-506) 1996 Aust N Z J Med pmid:8744629
Hashino S et al. Antitumor effect in cyclosporine A- or FK506-treated mice after syngeneic bone marrow transplantation. 1996 Leuk. Lymphoma pmid:8726416
Ichinari H et al. Effects of portal venous inoculation with donor splenocytes on lung allograft survival in dogs. 1996 J. Thorac. Cardiovasc. Surg. pmid:8751494
Steiner JP et al. Immunophilin regulation of neurotransmitter release. 1996 Mol. Med. pmid:8784785
Sunyecz JA et al. Lymphoproliferative disorder involving the cervix in a patient being treated with FK-506. 1996 Gynecol. Oncol. pmid:8751565
Herzog D et al. Combined bowel-liver transplantation in an infant with microvillous inclusion disease. 1996 J. Pediatr. Gastroenterol. Nutr. pmid:8732907
Ho SN et al. Dimeric ligands define a role for transcriptional activation domains in reinitiation. 1996 Nature pmid:8752278
Taler SJ et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. 1996 Transplantation pmid:8970613
Shuker SB et al. Discovering high-affinity ligands for proteins: SAR by NMR. 1996 Science pmid:8929414
Laskow DA et al. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. 1996 Transplantation pmid:8878381
Woodle ES et al. Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologic response by protocol biopsies. 1996 Transplantation pmid:8878382
Kershner RP and Fitzsimmons WE Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. 1996 Transplantation pmid:8878385
Tojimbara T et al. Cyclosporine and tacrolimus both suppress activation of Kupffer cells in vitro. 1996 Transplant. Proc. pmid:8658704
Nolan TJ and Schad GA Tacrolimus allows autoinfective development of the parasitic nematode Strongyloides stercoralis. 1996 Transplantation pmid:8878405
Yuzawa K et al. Topical immunosuppression in skin grafting with FK 506 ointment. 1996 Transplant. Proc. pmid:8658707
Yagura K et al. Pharmacokinetic characteristics of two types of liposomal FK 506. 1996 Transplant. Proc. pmid:8658708
Ogawa N et al. Suppressive effects of combination therapy with mizoribine and FK 506 on the development of accelerated coronary artery disease and myocardial rejection after heart transplantation. 1996 Transplant. Proc. pmid:8658710
Yoshida Y et al. Effect of lipoprostaglandin E1 in concordant xenografts. 1996 Transplant. Proc. pmid:8658716
Kawauchi M et al. Which are the target vessels of xeno- and allo-lung rejection?--a primate single lung transplantation study. 1996 Transplant. Proc. pmid:8658719
Sakimoto H et al. Administration of tacrolimus (FK506) in hamster-to-rat pancreas xenotransplantation. 1996 Transplant. Proc. pmid:8658727
Takeda M et al. Pretreatment with splenectomy and FK506 in xeno-lung transplantation. 1996 Transplant. Proc. pmid:8658728
McCall E et al. Effects of FK-506 on contraction and Ca2+ transients in rat cardiac myocytes. 1996 Circ. Res. pmid:8943949
Winkler M et al. Evaluation of the Pro-Trac tacrolimus monoclonal whole-blood enzyme-linked immunosorbent assay for monitoring of tacrolimus levels in patients after kidney, heart, and liver transplantation. 1996 Ther Drug Monit pmid:8946659
Nichterlein T et al. Effects of FK-506 on the course of murine salmonellosis. 1996 J Chemother pmid:8981186
MacFarlane G et al. A simplified whole blood enzyme-linked immunosorbent assay (ProTrac II) for tacrolimus (FK506) using proteolytic extraction in place of organic solvents. 1996 Ther Drug Monit pmid:8946668
Redmon JB et al. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. 1996 J. Clin. Invest. pmid:8981925
Brunet M et al. Comparative analysis of tacrolimus (FK506) in whole blood liver transplant recipients by PRO-TRAC enzyme-linked immunosorbent assay and microparticle enzyme immunoassay IMX methods. 1996 Ther Drug Monit pmid:8946669
Sempuku T et al. Osteogenic potential of allogeneic rat marrow cells in porous hydroxyapatite ceramics: a histological study. 1996 J. Orthop. Res. pmid:8982133
Iwata M et al. Regulation of T cell apoptosis via T cell receptors and steroid receptors. 1996 Stem Cells pmid:8948021
Holt DW et al. Quality assessment issues of new immunosuppressive drugs and experimental experience. 1996 Ther Drug Monit pmid:8857551
McMichael J et al. Computer-guided randomized concentration-controlled trials of tacrolimus in autoimmunity: multiple sclerosis and primary biliary cirrhosis. 1996 Ther Drug Monit pmid:8857564
Fealy MJ and Press BH Pinpointing the moment of allograft rejection. 1996 J Hand Surg Am pmid:8724501
Hall MN The TOR signalling pathway and growth control in yeast. 1996 Biochem. Soc. Trans. pmid:8674674
Mattila PS The actions of cyclosporin A and FK506 on T-lymphocyte activation. 1996 Biochem. Soc. Trans. pmid:8674715
Adams DH and Liu Q FK506 inhibits human lymphocyte migration and the production of lymphocyte chemotactic factors in liver allograft recipients. 1996 Hepatology pmid:8675167
Halloran PF Molecular mechanisms of new immunosuppressants. 1996 Clin Transplant pmid:8680047
Luan S et al. Molecular characterization of a FKBP-type immunophilin from higher plants. 1996 Proc. Natl. Acad. Sci. U.S.A. pmid:8692927
Bashuda H et al. Induction of persistent allograft tolerance in the rat by combined treatment with anti-leukocyte function-associated antigen-1 and anti-intercellular adhesion molecule-1 monoclonal antibodies, donor-specific transfusion, and FK506. 1996 Transplantation pmid:8693525
Barkholt LM et al. Epstein-Barr virus DNA in serum after liver transplantation--surveillance of viral activity during treatment with different immunosuppressive agents. 1996 Transpl. Int. pmid:8875785
Shapiro R et al. Tacrolimus in pediatric renal transplantation. 1996 Transplantation pmid:8990356
Morris-Stiff G et al. Haemolytic uraemic syndrome associated with OKT3. 1996 Transpl. Int. pmid:8875800
Przepiorka D et al. Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. 1996 Transplantation pmid:8990368
Kitagawa H et al. Cloning and high expression of rabbit FKBP25 in cornea. 1996 Jpn. J. Ophthalmol. pmid:8876379
Benelli U et al. FK-506 delays corneal graft rejection in a model of corneal xenotransplantation. 1996 J Ocul Pharmacol Ther pmid:8951679
Ueda S et al. In-vitro metabolic studies of tacrolimus using precision-cut rat and human liver slices. 1996 J Pharm Biomed Anal pmid:8951695
Richardson D et al. The successful conversion to Tacrolimus (FK506) of a renal transplant recipient with cyclosporin-induced haemolytic-uraemic syndrome. 1996 Nephrol. Dial. Transplant. pmid:9017633
Chambraud B et al. FAP48, a new protein that forms specific complexes with both immunophilins FKBP59 and FKBP12. Prevention by the immunosuppressant drugs FK506 and rapamycin. 1996 J. Biol. Chem. pmid:8955134
Sano Y et al. Effect of a single injection of high-dose FK506 on lung transplantation in rats. 1996 Surg. Today pmid:9017963
Villalba L and Adams EM Update on therapy for refractory dermatomyositis and polymyositis. 1996 Curr Opin Rheumatol pmid:9018458
Soubrane O and Houssin D [Liver transplantation. Current aspects]. 1996 Presse Med pmid:8728904
Lampen A et al. Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber. 1996 Br. J. Pharmacol. pmid:8732283
Saada V et al. Comparative evaluation of in vitro and in vivo immunosuppressive potential of cyclosporin G with cyclosporin A and FK-506. 1996 Int. J. Immunopharmacol. pmid:8732436
Inomata Y et al. The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. 1996 Transplantation pmid:8600632
Asante-Korang A et al. Experience of FK506 immune suppression in pediatric heart transplantation: a study of long-term adverse effects. 1996 J. Heart Lung Transplant. pmid:8732602
Gruessner RW et al. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. 1996 Transplantation pmid:8600635
Rifai N et al. The role of lipoproteins in the transport and uptake of cyclosporine and dihydro-tacrolimus into HepG2 and JURKAT cell lines. 1996 Clin. Biochem. pmid:8601324
Vilquin JT et al. Partial laminin alpha2 chain restoration in alpha2 chain-deficient dy/dy mouse by primary muscle cell culture transplantation. 1996 J. Cell Biol. pmid:8601607
Schuetz EG et al. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. 1996 Mol. Pharmacol. pmid:8632764
Sun S et al. Effect of tacrolimus on hemodynamics and absorption of experimental small intestinal transplants. 1996 Transplantation pmid:8633368